Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis

NCT02296775 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

276

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL: DRL_RI
BIOLOGICAL: Rituxan
BIOLOGICAL: MabThera

Sponsor

Dr. Reddy's Laboratories Limited